Agilent Q3 Revenues Increase 22 Percent, Life Sciences up 21 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fiscal third-quarter revenues rose 22 percent year over year with its Life Sciences segment seeing 21 percent growth, Agilent Technologies reported after the close of the market on Monday.

For the three months ended July 31, total revenues came in at $1.69 billion, compared to $1.38 billion a year ago, beating analyst estimates of $1.66 billion. Orders for the quarter increased 13 percent to $1.69 billion from $1.49 billion a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.